KIORA PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
KIORA PHARMACEUTICALS, INC. (KPRX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2019-03-01
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-12-31 was $0.00.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-09-30 was $0.00.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2018-03-31 was $0.00, a 100.00% decline year-over-year.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2018 was $0.00, a 100.00% decline from fiscal 2017.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2017 was $78.00K, a 62.32% decline from fiscal 2016.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2016 was $207.00K, a 53.33% increase from fiscal 2015.
- KIORA PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2015 was $135.00K.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | $0.00 derived: sum of 3 quarters · filed 2019-03-01 | $0.00 10-K · filed 2019-03-01 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $0.00 derived: sum of 2 quarters · filed 2018-11-13 | $0.00 10-Q · filed 2018-11-13 | $0.00 derived: sum of 4 quarters · filed 2019-03-01 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $0.00 10-Q · filed 2018-08-03 | $0.00 derived: sum of 3 quarters · filed 2019-03-01 | $0.00 derived: sum of 4 quarters · filed 2019-03-01 |
| 2018-03-31 | $0.00 10-Q · filed 2018-05-11 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | $0.00 derived: sum of 3 quarters · filed 2019-03-01 | $77.00K derived: sum of 4 quarters · filed 2019-03-01 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01 | $0.00 derived: sum of 2 quarters · filed 2019-03-01 | $77.00K derived: sum of 3 quarters · filed 2019-03-01 | $78.00K 10-K · filed 2019-03-01 |
| 2017-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-13 | $77.00K derived: sum of 2 quarters · filed 2018-11-13 | $78.00K 10-Q · filed 2018-11-13 | $78.00K derived: sum of 4 quarters · filed 2018-11-13 |
| 2017-06-30 | $77.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $78.00K 10-Q · filed 2018-08-03 | $78.00K derived: sum of 3 quarters · filed 2018-08-03 | $78.00K derived: sum of 4 quarters · filed 2018-08-03 |
| 2017-03-31 | $1.00K 10-Q · filed 2018-05-11 | $1.00K derived: sum of 2 quarters · filed 2018-05-11 | $1.00K derived: sum of 3 quarters · filed 2018-05-11 | $208.00K derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-02 | $0.00 derived: sum of 2 quarters · filed 2018-03-02 | $207.00K derived: sum of 3 quarters · filed 2018-03-02 | $207.00K 10-K · filed 2018-03-02 |
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-14 | $207.00K derived: sum of 2 quarters · filed 2017-11-14 | $207.00K 10-Q · filed 2017-11-14 | $215.00K derived: sum of 4 quarters · filed 2017-11-14 |
| 2016-06-30 | $207.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-04 | $207.00K 10-Q · filed 2017-08-04 | $215.00K derived: sum of 3 quarters · filed 2017-08-04 | |
| 2016-03-31 | $0.00 10-Q · filed 2017-05-05 | $8.00K derived: sum of 2 quarters · filed 2017-05-05 | ||
| 2015-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $135.00K 10-K · filed 2017-02-23 | ||
| 2015-09-30 | $127.00K 10-Q · filed 2016-11-01 | |||
| 2014-12-31 | $0.00 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |